ArticleCureus2026
Benchmarking a Local Schema-Constrained Large Language Model Pipeline for Abstract Screening and Evidence Mapping.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The growth of biomedical literature increasingly exceeds the capacity of manual evidence synthesis. Large language models (LLMs) may support abstract screening and structured extraction, but many current workflows depend on proprietary cloud APIs, creating challenges for governance, reproducibility, and scalable deployment. Methods I developed a fully local, open-weight, schema-constrained pipeline (gpt-oss-20b, deployed via Ollama on Apple M1 Max) for title/abstract-based scoping workflows. The pipeline combined deterministic metadata filtering, LLM-assisted screening, and structured abstract extraction. Performance was benchmarked against three published systematic reviews (ketamine/neuroimaging; clozapine/suicidality; clozapine patient/caregiver perspectives) using precision, recall, and F1 against reference inclusion sets. I also report audit-adjusted estimates (i.e., performance metrics recalculated after manual full-text adjudication of discrepant records) alongside standard reference-set performance. Results In the ketamine/neuroimaging benchmark, the pipeline retained all 41 studies included in the original review; after audit adjustment, recall was 100.0% (46/46), accuracy 99.4% (156/157), precision 97.9% (46/47), and F1 98.9%. For clozapine/suicidality, recall was 79.3% (46/58), and F1 was 76.0%, with missed studies largely attributable to missing or non-informative abstracts. For clozapine patient/caregiver perspectives, recall was 88.9% (56/63), and F1 was 83.6%, with similar abstract-level constraints. Abstract-level extraction recovered audited metadata fields without detected errors and generated evidence maps that were thematically concordant with the main narrative structure of the reference reviews. Conclusions As a proof-of-concept, a fully local LLM pipeline can support scalable and auditable abstract-based scoping and high-level evidence mapping. Because performance was benchmarked against three reviews with partly audit-adjusted reference sets, the findings require confirmation in larger, independently adjudicated evaluations. Random human audit remains advisable, and expert full-text synthesis remains necessary when abstracts are non-informative or when mechanistic precision is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.